United States-based Conformal Medical Inc has named George Fazio as its new director, it was reported on Thursday.
Presently, Fazio is the president and chief executive officer of Corvia Medical. He has over three decades of executive experience in the cardiovascular space. He has served in various senior leadership positions with St Jude Medical, including serving as president of the United States and EMEA regions, and both the cardiovascular and cardiac surgery businesses. He also held the position of president of Health Care Services.
Andy Levine, co-founder and chief executive officer of Conformal Medical, said, 'We are very pleased to have George join Conformal's board of directors at this important time as we embark on our US IDE trial. We are confident that his strategic business insights, extensive knowledge in the cardiovascular market, and experience as an executive of a private medical device company will add tremendous value as we advance our technology through upcoming clinical and regulatory milestones.'
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio